title: [Xenotransplantation of the liver].
abstract: The development of pigs transgenic for human regulators of complement activation resulted in the nearly total elimination of episodes of hyperacute rejection following discordant solid organ xenotransplantation. Following discordant heart or kidney transplantation, in subhuman primates, graft survival rates of up to several months can be observed. In contrast to these organs, the xenotransplantation of the liver is associated with the inherent problem of the immunological and metabolic compatibility of the large variety of xenoproteins generated. Based on a review of data mainly derived from experimental ex-vivo xenoliver perfusions in patients with hepatic coma, whole organ orthotopic or heterotopic liver xenotransplantation currently is not likely to become a relevant option for the treatment of patients with endstage liver failure. In contrast, clinical studies utilizing different forms of bioartificial liver assist devices are currently underway. Based on preliminary data published, this form of liver support therapy might enter the clinic in the near future.
authors.affiliation: Klinik für Abdominal- und Transplantationschirurgie, Medizinische Hochschule Hannover.
authors.forename: M
authors.initials: M
authors.lastname: Winkler
authors.forename: H J
authors.initials: HJ
authors.lastname: Schlitt
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D015478:Antigens, Heterophile / Q000276:immunology; D003167:Complement Activation / Q000235:genetics / Q000276:immunology; D018014:Gene Transfer Techniques; D006801:Humans; D007165:Immunosuppression Therapy; D016031:Liver Transplantation / Q000276:immunology; D013552:Swine; D014183:Transplantation, Heterologous / Q000276:immunology
chemical_list: D015478:Antigens, Heterophile